{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:39:02Z","timestamp":1780616342717,"version":"3.54.1"},"reference-count":86,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Small-cell lung cancer (SCLC) cases represent approximately 15% of all lung cancer cases, remaining a recalcitrant malignancy with poor survival and few treatment options. In the last few years, the addition of immunotherapy to chemotherapy improved clinical outcomes compared to chemotherapy alone, resulting in the current standard of care for SCLC. However, the advantage of immunotherapy only applies to a few SCLC patients, and predictive biomarkers selection are lacking for SCLC. In particular, due to some features of SCLC, such as high heterogeneity, elevated cell plasticity, and low-quality tissue samples, SCLC biopsies cannot be used as biomarkers. Therefore, the characterization of the tumor and, subsequently, the selection of an appropriate therapeutic combination may benefit greatly from liquid biopsy. Soluble factors, circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) are now useful tools in the characterization of SCLC. This review summarizes the most recent data on biomarkers detectable with liquid biopsy, emphasizing their role in supporting tumor detection and their potential role in SCLC treatment choice.<\/jats:p>","DOI":"10.3390\/biom14040396","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T12:47:11Z","timestamp":1711370831000},"page":"396","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Small-Cell Lung Cancer: Is Liquid Biopsy a New Tool Able to Predict the Efficacy of Immunotherapy?"],"prefix":"10.3390","volume":"14","author":[{"given":"Rossella","family":"Fasano","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Pharmacology, IRCCS Istituto Tumori Giovanni Paolo II, V.Le O. Flacco, 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-5205","authenticated-orcid":false,"given":"Simona","family":"Serrat\u00ec","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Pharmacology, IRCCS Istituto Tumori Giovanni Paolo II, V.Le O. Flacco, 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Rafaschieri","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Pharmacology, IRCCS Istituto Tumori Giovanni Paolo II, V.Le O. Flacco, 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Longo","sequence":"additional","affiliation":[{"name":"Medical Thoracic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Di Fonte","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Pharmacology, IRCCS Istituto Tumori Giovanni Paolo II, V.Le O. Flacco, 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Porcelli","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Pharmacology, IRCCS Istituto Tumori Giovanni Paolo II, V.Le O. Flacco, 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6149-5049","authenticated-orcid":false,"given":"Amalia","family":"Azzariti","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Pharmacology, IRCCS Istituto Tumori Giovanni Paolo II, V.Le O. Flacco, 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","article-title":"SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection","volume":"18","author":"Wang","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jtho.2020.01.016","article-title":"New Approaches to SCLC Therapy: From the Laboratory to the Clinic","volume":"15","author":"Poirier","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated Overall Survival and PD-L1 Subgroup Analysis of Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Atezolizumab, Carboplatin, and Etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_4","first-page":"S565","article-title":"Chemotherapy Advances in Small-Cell Lung Cancer","volume":"5","author":"Chan","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without Tremelimumab, plus Platinum\u2013Etoposide versus Platinum\u2013Etoposide Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): Updated Results from a Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1002\/cncr.34977","article-title":"Advancing Immunotherapy in Small Cell Lung Cancer","volume":"129","author":"Carlisle","year":"2023","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or Placebo plus Carboplatin and Etoposide as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer (CAPSTONE-1): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients with Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.jtho.2023.09.027","article-title":"OA01.06 First-Line Chemotherapy with or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study","volume":"18","author":"Cheng","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jtho.2023.09.024","article-title":"OA01.03 Benmelstobart with Anlotinib plus Chemotherapy as First-Line Therapy for ES-SCLC: A Randomized, Double-Blind, Phase III Trial","volume":"18","author":"Cheng","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jtho.2016.09.002","article-title":"PD-L1 Expression by Two Complementary Diagnostic Assays and MRNA In Situ Hybridization in Small Cell Lung Cancer","volume":"12","author":"Yu","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","article-title":"PD-L1 Expression in Lung Cancer","volume":"11","author":"Yu","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","article-title":"Expression and Clinical Significance of PD-L1, B7-H3, B7-H4 and TILs in Human Small Cell Lung Cancer (SCLC)","volume":"7","author":"Altan","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejca.2014.12.006","article-title":"PD-L1 Expression in Small Cell Neuroendocrine Carcinomas","volume":"51","author":"Schultheis","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100408","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without Tremelimumab, plus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: 3-Year Overall Survival Update from CASPIAN","volume":"7","author":"Chen","year":"2022","journal-title":"ESMO Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1158\/1078-0432.CCR-23-3087","article-title":"In Search of Lost Biomarker for Immunotherapy in Small-Cell Lung Cancer","volume":"30","author":"Rolfo","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC with Distinct Therapeutic Vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"CT024","DOI":"10.1158\/1538-7445.AM2022-CT024","article-title":"Abstract CT024: Durvalumab (D) + Platinum-Etoposide (EP) in 1L Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): Exploratory Analysis of SCLC Molecular Subtypes in CASPIAN","volume":"82","author":"Xie","year":"2022","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Yee, N.S. (2020). Liquid Biopsy: A Biomarker-Driven Tool towards Precision Oncology. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082556"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zamay, T.N., Zamay, G.S., Kolovskaya, O.S., Zukov, R.A., Petrova, M.M., Gargaun, A., Berezovski, M.V., and Kichkailo, A.S. (2017). Current and Prospective Protein Biomarkers of Lung Cancer. Cancers, 9.","DOI":"10.3390\/cancers9110155"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.lungcan.2023.01.014","article-title":"Liquid Biopsy-Based Decision Support Algorithms for Diagnosis and Subtyping of Lung Cancer","volume":"178","author":"Visser","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.semcancer.2022.05.004","article-title":"Small Cell Lung Cancer: Novel Treatments beyond Immunotherapy","volume":"86","author":"Meijer","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nm.3600","article-title":"Tumorigenicity and Genetic Profiling of Circulating Tumor Cells in Small-Cell Lung Cancer","volume":"20","author":"Hodgkinson","year":"2014","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hofman, V., Heeke, S., Marquette, C.H., Ili\u00e9, M., and Hofman, P. (2019). Circulating Tumor Cell Detection in Lung Cancer: But to What End?. Cancers, 11.","DOI":"10.3390\/cancers11020262"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","article-title":"Unravelling Tumour Heterogeneity by Single-Cell Profiling of Circulating Tumour Cells","volume":"19","author":"Keller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.7150\/jca.35308","article-title":"Circulating Tumor Cells as a New Predictive and Prognostic Factor in Patients with Small Cell Lung Cancer","volume":"11","author":"Wang","year":"2020","journal-title":"J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fon.15.346","article-title":"Circulating Tumor Cell Counts\/Change for Outcome Prediction in Patients with Extensive-Stage Small-Cell Lung Cancer","volume":"12","author":"Cheng","year":"2016","journal-title":"Future Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/annonc\/mdz122","article-title":"Prognostic Value of Circulating Tumour Cells in Limited-Stage Small-Cell Lung Cancer: Analysis of the Concurrent Once-Daily versus Twice-Daily Radiotherapy (CONVERT) Randomised Controlled Trial","volume":"30","author":"Tay","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1111\/1759-7714.14120","article-title":"Circulating Tumor Cells (CTCs)\/Circulating Tumor Endothelial Cells (CTECs) and Their Subtypes in Small Cell Lung Cancer: Predictors for Response and Prognosis","volume":"12","author":"Zhu","year":"2021","journal-title":"Thorac. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1126\/science.1228522","article-title":"Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition","volume":"339","author":"Yu","year":"2013","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Hanin, L. (2023). The Circulation Stage of the Metastatic Cascade: A Mathematical Description and Its Clinical Implications. J. Theor. Biol., 572.","DOI":"10.1016\/j.jtbi.2023.111582"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-Mesenchymal Transitions in Development and Disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e915","DOI":"10.1038\/cddis.2013.442","article-title":"An EMT Spectrum Defines an Anoikis-Resistant and Spheroidogenic Intermediate Mesenchymal State That Is Sensitive to e-Cadherin Restoration by a Src-Kinase Inhibitor, Saracatinib (AZD0530)","volume":"4","author":"Huang","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Vu, T., Jin, L., and Datta, P.K. (2016). Effect of Cigarette Smoking on Epithelial to Mesenchymal Transition (EMT) in Lung Cancer. J. Clin. Med., 5.","DOI":"10.3390\/jcm5040044"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncb2173","article-title":"P53 Regulates Epithelial-Mesenchymal Transition and Stem Cell Properties through Modulating MiRNAs","volume":"13","author":"Chang","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"418","DOI":"10.21037\/tlcr.2017.07.04","article-title":"Circulating Tumor Cell Interactions with Macrophages: Implications for Biology and Treatment","volume":"6","author":"Hamilton","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-3-319-55947-6_12","article-title":"Mesenchymal-Epithelial Transition and Circulating Tumor Cells in Small Cell Lung Cancer","volume":"994","author":"Hamilton","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e1093277","DOI":"10.1080\/2162402X.2015.1093277","article-title":"Small Cell Lung Cancer: Recruitment of Macrophages by Circulating Tumor Cells","volume":"5","author":"Hamilton","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10555-022-10067-x","article-title":"Physicochemical Aspects of the Tumour Microenvironment as Drivers of Vasculogenic Mimicry","volume":"41","author":"Andreucci","year":"2022","journal-title":"Cancer Metastasis Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/jcmm.12851","article-title":"The Relationship between Vasculogenic Mimicry and Epithelial-Mesenchymal Transitions","volume":"20","author":"Liu","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"13322","DOI":"10.1038\/ncomms13322","article-title":"Vasculogenic Mimicry in Small Cell Lung Cancer","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"109116","DOI":"10.1016\/j.intimp.2022.109116","article-title":"Immunotherapy Checkpoints in Ovarian Cancer Vasculogenic Mimicry: Tumor Immune Microenvironments, and Drugs","volume":"111","author":"Hu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1200\/JCO.2010.33.3716","article-title":"Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients with Small-Cell Lung Cancer","volume":"30","author":"Hou","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"877","DOI":"10.21037\/tlcr-22-712","article-title":"Significance of Circulating Tumor Cells in Lung Cancer: A Narrative Review","volume":"12","author":"Hamilton","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10354-015-0381-6","article-title":"Smoking, Inflammation and Small Cell Lung Cancer: Recent Developments","volume":"165","author":"Hamilton","year":"2015","journal-title":"Wiener Med. Wochenschr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","article-title":"Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis","volume":"158","author":"Aceto","year":"2014","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1038\/s41598-017-05562-z","article-title":"Small Cell Lung Cancer: Model of Circulating Tumor Cell Tumorospheres in Chemoresistance","volume":"7","author":"Klameth","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/1878-0261.12869","article-title":"Clinical Utility of Circulating Tumor Cells: An Update","volume":"15","author":"Vasseur","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/14712598.2019.1592155","article-title":"Immunotherapy for Small Cell Lung Cancer: Mechanisms of Resistance","volume":"19","author":"Hamilton","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41598-017-00520-1","article-title":"Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types","volume":"7","author":"Shu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_52","first-page":"1659","article-title":"DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","article-title":"Early Reduction in CtDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab","volume":"24","author":"Raja","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.mehy.2005.04.042","article-title":"Circulation DNA: Biological Implications for Cancer Metastasis and Immunology","volume":"65","author":"Chen","year":"2005","journal-title":"Med. Hypotheses"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s43018-022-00415-9","article-title":"CfDNA Methylome Profiling for Detection and Subtyping of Small Cell Lung Cancers","volume":"3","author":"Chemi","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2024.01.001","article-title":"Tumor- and Circulating-Free DNA Methylation Identifies Clinically Relevant Small Cell Lung Cancer Subtypes","volume":"42","author":"Heeke","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.lungcan.2023.01.015","article-title":"Prognostic Value of Circulating Tumor DNA Using Target Next-Generation Sequencing in Extensive-Stage Small-Cell Lung Cancer","volume":"178","author":"Zhang","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Herbreteau, G., Langlais, A., Greillier, L., Audigier-Valette, C., Uwer, L., Hureaux, J., Moro-Sibilot, D., Guisier, F., Carmier, D., and Madelaine, J. (2020). Circulating Tumor Dna as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab. J. Clin. Med., 9.","DOI":"10.3390\/jcm9123861"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s12032-013-0662-0","article-title":"Soluble ICAM-1 Levels in Small-Cell Lung Cancer: Prognostic Value for Survival and Predictive Significance for Response during Chemotherapy","volume":"30","author":"Kotteas","year":"2013","journal-title":"Med. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"403","DOI":"10.7150\/ijms.28814","article-title":"Prognostic Significance of Serum Soluble DR5 Levels in Small-Cell Lung Cancer","volume":"16","author":"Wan","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"19712","DOI":"10.1038\/s41598-021-99311-y","article-title":"Soluble PD-L1 Is a Predictive and Prognostic Biomarker in Advanced Cancer Patients Who Receive Immune Checkpoint Blockade Treatment","volume":"11","author":"Oh","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12931-018-0885-x","article-title":"Elevated Serum Soluble Programmed Cell Death Ligand 1 Concentration as a Potential Marker for Poor Prognosis in Small Cell Lung Cancer Patients with Chemotherapy","volume":"19","author":"Jin","year":"2018","journal-title":"Respir. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e1593810","DOI":"10.1080\/2162402X.2019.1593810","article-title":"Serum Cytokine Levels as Predictive Biomarkers of Benefit from Ipilimumab in Small Cell Lung Cancer","volume":"8","author":"Rocha","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12964-023-01103-6","article-title":"A Review of the Regulatory Mechanisms of Extracellular Vesicles-Mediated Intercellular Communication","volume":"21","author":"Liu","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018): A Position Statement of the International Society for Extracellular Vesicles and Update of the MISEV2014 Guidelines","volume":"7","author":"Witwer","year":"2018","journal-title":"J. Extracell. Vesicles"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Repetto, O., Vettori, R., Steffan, A., Cannizzaro, R., and De Re, V. (2023). Circulating Proteins as Diagnostic Markers in Gastric Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316931"},{"key":"ref_67","first-page":"5254","article-title":"PRDM16 from Hepatic Stellate Cells-Derived Extracellular Vesicles Promotes Hepatocellular Carcinoma Progression","volume":"13","author":"Sun","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Serrat\u00ec, S., Porcelli, L., Fragassi, F., Garofoli, M., Di Fonte, R., Fucci, L., Iacobazzi, R.M., Palazzo, A., Margheri, F., and Cristiani, G. (2021). The Interaction between Reactive Peritoneal Mesothelial Cells and Tumor Cells via Extracellular Vesicles Facilitates Colorectal Cancer Dissemination. Cancers, 13.","DOI":"10.3390\/cancers13102505"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s13046-023-02916-6","article-title":"Circular RNA CircATP9A Promotes Non-Small Cell Lung Cancer Progression by Interacting with HuR and by Promoting Extracellular Vesicles-Mediated Macrophage M2 Polarization","volume":"42","author":"Yao","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"104220","DOI":"10.1016\/j.critrevonc.2023.104220","article-title":"Clinical Relevance of Exosome-Derived MicroRNAs in Ovarian Cancer: Looking for New Tumor Biological Fingerprints","volume":"193","author":"Fanale","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-021-01490-9","article-title":"Circulating Extracellular Vesicles Expressing PD1 and PD-L1 Predict Response and Mediate Resistance to Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma","volume":"21","author":"Guida","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13046-023-02808-9","article-title":"Circulating Extracellular Vesicles Are Monitoring Biomarkers of Anti-PD1 Response and Enhancer of Tumor Progression and Immunosuppression in Metastatic Melanoma","volume":"42","author":"Porcelli","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Martinez-Espinosa, I., Serrato, J.A., and Ortiz-Quintero, B. (2023). The Role of Exosome-Derived MicroRNA on Lung Cancer Metastasis Progression. Biomolecules, 13.","DOI":"10.3390\/biom13111574"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2174\/1568026623666221124110016","article-title":"Surface Functionalization of Extracellular Vesicles with Nucleic Acids towards Biomedical Applications","volume":"23","author":"Xu","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2165\/00003495-200767150-00003","article-title":"Modern Management of Small-Cell Lung Cancer","volume":"67","author":"Ferraldeschi","year":"2007","journal-title":"Drugs"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jtho.2016.08.122","article-title":"Exosomal Proteins in Lung Cancer: The Last Frontier in Liquid Biopsies","volume":"11","author":"Rolfo","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jtho.2016.05.034","article-title":"Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer","volume":"11","author":"Jakobsen","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_78","first-page":"9813773","article-title":"Exosomal LncRNA SCIRT\/MiR-665 Transferring Promotes Lung Cancer Cell Metastasis through the Inhibition of HEYL","volume":"2021","author":"Wang","year":"2021","journal-title":"J. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3349\/ymj.2022.63.3.229","article-title":"MEG3 LncRNA from Exosomes Released from Cancer-Associated Fibroblasts Enhances Cisplatin Chemoresistance in SCLC via a MiR-15a-5p\/CCNE1 Axis","volume":"63","author":"Sun","year":"2022","journal-title":"Yonsei Med. J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.2147\/IJN.S407116","article-title":"Extracellular Vesicles Derived CircSH3PXD2A Inhibits Chemoresistance of Small Cell Lung Cancer by MiR-375-3p\/YAP1","volume":"18","author":"Chao","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"15365","DOI":"10.1007\/s00432-023-05317-6","article-title":"Hsa_circ_0041150 Serves as a Novel Biomarker for Monitoring Chemotherapy Resistance in Small Cell Lung Cancer Patients Treated with a First-Line Chemotherapy Regimen","volume":"149","author":"Zhang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.7150\/jca.75622","article-title":"A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)","volume":"13","author":"Oronsky","year":"2022","journal-title":"J. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-022-00763-8","article-title":"The Roles of Extracellular Vesicles in the Immune System","volume":"23","author":"Buzas","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41419-022-05336-0","article-title":"NLRP6 Is Required for Cancer-Derived Exosome-Modified Macrophage M2 Polarization and Promotes Metastasis in Small Cell Lung Cancer","volume":"13","author":"Rao","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"874589","DOI":"10.3389\/fimmu.2022.874589","article-title":"Tumor-Associated Macrophages Regulate PD-1\/PD-L1 Immunosuppression","volume":"13","author":"Pu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/cei\/uxac006","article-title":"Extracellular Vesicles Containing PD-L1 Contribute to CD8+T-Cell Immune Suppression and Predict Poor Outcomes in Small Cell Lung Cancer","volume":"207","author":"Dou","year":"2022","journal-title":"Clin. Exp. Immunol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/4\/396\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:18:31Z","timestamp":1760105911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/4\/396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":86,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["biom14040396"],"URL":"https:\/\/doi.org\/10.3390\/biom14040396","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]}}}